Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2021 September;63(3) > Panminerva Medica 2021 September;63(3):324-31

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   Freefree

Panminerva Medica 2021 September;63(3):324-31

DOI: 10.23736/S0031-0808.21.04435-9

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache

Armando PERROTTA 1, Giuseppe BIONDI-ZOCCAI 2, 3, Wael SAADE 4, Fabio MIRALDI 4, Andrea MORELLI 4, Antonino G. MARULLO 2, Elena CAVARRETTA 2, 3, Roberto CARNEVALE 2, 3, Elena DE FALCO 2, 3, Isotta CHIMENTI 2, 3, Sebastiano SCIARRETTA 1, 2, Paola FRATI 1, 5, Mamas A. MAMAS 6, 7, Sara CIARDI 8, Luigi FRATI 1, 9, Giacomo FRATI 1, 2, Mariangela PERUZZI 3, 4

1 IRCCS NEUROMED, Pozzilli, Isernia, Italy; 2 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy; 3 Mediterranea Cardiocentro, Naples, Italy; 4 Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University, Rome, Italy; 5 Department of Anatomical Histological, Forensis and Orthopedic Sciences, Sapienza University, Rome, Italy; 6 Keele Cardiovascular Research Group, Institutes of Applied Clinical Science and Primary Care and Health Sciences, University Hospital of North Midlands, Keele University, Stoke-on-Trent, UK; 7 Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, UK; 8 Carabinieri Corps Health Service, Rome, Italy; 9 Pasteur Institute, Rome, Italy



BACKGROUND: New messenger RNA (mRNA) and adenovirus-based vaccines (AdV) against Coronavirus disease 2019 (COVID-19) have entered large scale clinical trials. Since healthcare professionals (HCPs) and armed forces personnel (AFP) represent a high-risk category, they act as a suitable target population to investigate vaccine-related side effects, including headache, which has emerged as a common complaint.
METHODS: We investigated the side-effects of COVID-19 vaccines among HCPs and AFP through a 38 closed-question international survey. The electronic link was distributed via e-mail or via Whatsapp to more than 500 contacts. Responses to the survey questions were analyzed with bivariate tests.
RESULTS: A total of 375 complete surveys have been analyzed. More than 88% received an mRNA vaccine and 11% received AdV first dose. A second dose of mRNA vaccine was administered in 76% of individuals. No severe adverse effects were reported, whereas moderate reactions and those lasting more than 1 day were more common with AdV (P=0.002 and P=0.024 respectively). Headache was commonly reported regardless of the vaccine type, but less frequently, with shorter duration and lower severity that usually experienced by participants, without significant difference irrespective of vaccine type.
CONCLUSIONS: Both mRNA and AdV COVID-19 vaccines were safe and well tolerated in a real-life subset of HCPs and AFP subjects.


KEY WORDS: COVID-19; Headache; Surveys and questionnaires; Vaccines

inizio pagina